Immutep (ASX:IMM), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, has announced that Lis Boyce has been appointed as a non-executive director.
Ms Boyce replaces Lucy Turnbull. She is a highly experienced corporate lawyer and is currently a partner at Piper Alderman. She was previously a partner at Dentons, having been at DibbsBarker for nearly 30 years. She has extensive involvement in the Life Sciences and Healthcare sectors and is currently deputy chair of AusBiotech’s AusMedtech Advisory Group and a member of AusBiotech’s NSW Leadership Committee.
Immutep chair Dr Russell Howard said, “We are delighted to have Lis join our board. She brings a wealth of industry knowledge and expertise in capital raisings, strategic collaborations, corporate governance, and mergers and acquisitions. On behalf of the Board, I would like to thank Lucy Turnbull for stepping in under such tragic and unusual circumstances and for her boundless energy and valued insights.”